AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Pemgli-M2 Tablet ER

Prescription Icon
Prescription Required

Marketer

Superlative Healthcare

Salt Composition

Glimepiride (2mg) + Metformin (500mg)

Overview Pemgli-M2 Tablet ER

DiaGlym-XR, a dual-action antidiabetic medication, combines two agents to manage type 2 diabetes in adults. It effectively regulates blood glucose. DiaGlym-XR should be ingested with food, consistently at the same time daily for optimal results. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical supervision can elevate blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. DiaGlym-XR complements a comprehensive diabetes management plan including diet, exercise, and weight management as directed by your doctor. Lifestyle choices are vital in diabetes control. Hypoglycemia (low blood sugar) is a common side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary snacks, juice) are essential. Alcohol consumption increases hypoglycemia risk and should be limited. Additional potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. DiaGlym-XR is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before starting this medication. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring and periodic blood tests (to assess blood cell counts and liver function) are recommended.

Primary Ingredients of Pemgli-M2 Tablet ER

No text provided. Please provide the text you wish me to rephrase.

Uses of Pemgli-M2 Tablet ER

Managing type 2 diabetes

Major Benefits of Pemgli-M2 Tablet ER:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Pemgli-M2 Tablet ER with a meal.

Common Side effects of Pemgli-M2 Tablet ER:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Pemgli-M2 Tablet ER:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Pemgli-M2 Extended-Release Tablets should be administered with food.

How Pemgli-M2 Tablet ER works:

Pemgli-M2 Extended-Release tablets contain glimepiride and metformin, two medications used to manage diabetes. Glimepiride, a sulfonylurea, stimulates the pancreas to produce more insulin, thus reducing blood sugar levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose uptake, and enhancing insulin responsiveness in tissues.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol while taking Pemgli-M2 Tablet ER is dangerous.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Pemgli-M2 tablets might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Extended-release Pemgli-M2 tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Exercise caution when administering Pemgli-M2 ER tablets to individuals with kidney impairment; dosage modification may be necessary. Consult your physician for guidance. Pemgli-M2 ER tablets are contraindicated in patients exhibiting severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverCAUTION

Exercise caution when prescribing Pemgli-M2 Extended-Release tablets to patients with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised. For individuals with mild to moderate liver disease, initiate treatment with a reduced Pemgli-M2 ER dose; the medication is contraindicated in those with severe liver dysfunction.

What if you forget to take Pemgli-M2 Tablet ER :

Should you forget a Pemgli-M2 Tablet ER dose, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Pemgli-M2 Tablet ER

LabelValue
Developing Good Habits No.
Treatment Category Diabetes Management

FAQs on Pemgli-M2 Tablet ER

Store this medication in its original, tightly closed container, as directed on the label or packaging. Discard any unused medication; keep it out of reach of children, pets, and others.
Pemgli-M2 Tablet ER can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare but potentially harmful side effect is more likely in patients with kidney disease, the elderly, or those who consume large amounts of alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If these occur, discontinue Pemgli-M2 Tablet ER and seek immediate medical attention.
Pemgli-M2 ER tablets combine glimepiride and metformin to manage type 2 diabetes mellitus (DM) in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for treating type 1 DM.
Pemgli-M2 Tablet ER may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, and headache. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Prolonged Pemgli-M2 Tablet ER use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may result in anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and ataxia), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Pemgli-M2 ER tablets can cause low blood sugar (hypoglycemia), characterized by nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, and shakiness or anxiety. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Therefore, regular blood sugar monitoring is crucial. Always carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice.
Combining Pemgli-M2 Tablet ER and alcohol is unsafe. Alcohol can worsen the drug's blood sugar-lowering effect, potentially causing hypoglycemia and increasing the risk of lactic acidosis.
Pemgli-M2 Tablet ER
54
MRP 66
18% off